RecruitingPhase 2

buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest

United States30 participantsStarted 2023-08-07

Plain-language summary

RESTORE is a randomized clinical trial investigating the safety and feasibility of using EEG treatment targets (burst suppression vs. seizure suppression) for post-cardiac arrest refractory status epilepticus treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥18 years old
✓. Non-traumatic, out-of-hospital cardiac arrest
✓. Comatose on admission - defined as not following commands
✓. Return of spontaneous circulation (ROSC) within less than 45 minutes
✓. Admission to the intensive care unit
✓. Diagnosis of post-cardiac arrest refractory status epilepticus confirmed with continuous

Exclusion criteria

✕. Acute cerebral hemorrhage or infarction
✕. Pregnancy
✕. Prisoners

What they're measuring

Post-cardiac arrest refractory status epilepticus control

Timeframe: 48 hours

Trial details

NCT IDNCT05851391

SponsorUniversity of California, San Francisco

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-11-30

Contact for this trial

Edilberto Amorim, MD

628-206-3203 restorestudy@ucsf.edu

View on ClinicalTrials.gov More Hypoxia-Ischemia, Brain trials